Core Insights - Passage Bio, Inc. has appointed Tom Kassberg to its Board of Directors and Audit Committee, enhancing its leadership team during a critical phase for the organization [1][2] - Mr. Kassberg brings extensive experience from Ultragenyx, where he contributed to the development of gene therapies for rare diseases, which will be beneficial for Passage Bio's strategic direction [2][3] Company Overview - Passage Bio is a clinical stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases, with its lead product candidate PBFT02 aimed at treating conditions like frontotemporal dementia [4] - The company aims to elevate progranulin levels to restore lysosomal function and slow disease progression in patients [4] Leadership Experience - Tom Kassberg has a strong background in corporate development and strategic planning, having held key positions at various biopharmaceutical companies, including Proteolix and InterMune [2][3] - His career includes significant contributions to business development and alliance management, which are expected to support Passage Bio's mission [2][3]
Passage Bio Welcomes Tom Kassberg to Board of Directors